Nothing in this article constitutes medical advice or a recommendation for self-administration.
Oral semaglutide (Rybelsus) has reshaped type 2 diabetes management since its 2019 FDA approval, and its off-label use for weight loss is climbing. Anecdotal reports of "brain fog" , mental clouding, slower recall, reduced focus , have surfaced in patient forums and social media. Whether these effects stem from rapid metabolic shifts, caloric restriction, or direct central actions of GLP-1 receptor agonism remains unclear. For researchers tracking nootropic interventions, Selank , a synthetic heptapeptide derived from tuftsin , has drawn attention for its anxiolytic and cognition-sparing properties. This reading list surveys the evidence base, with a focus on how Selank might intersect with GLP-1-related cognitive changes.
Why This Reading List
GLP-1 receptor agonists are not known to be directly neurotoxic, but the metabolic environment they create can stress cognitive systems. A 2022 review in Frontiers in Endocrinology noted that rapid weight loss and improved glycaemic control can transiently disrupt brain energy homeostasis (PubMed). Meanwhile, Selank has been studied since the 1990s in Russia for anxiety and memory, with a 2019 trial showing it improved cognitive performance in patients with generalised anxiety disorder (PubMed). The peptide's mechanism , modulating GABAergic and monoaminergic systems while increasing brain-derived neurotrophic factor (BDNF) , suggests a profile that could buffer the cognitive cost of metabolic upheaval. This reading list prioritises review articles and controlled trials, acknowledging that most Selank data come from small, Russian-language studies (evidence quality: 2 of 3).
Paper 1: The Cognitive Safety Profile of GLP-1 Agonists
A 2021 systematic review in Diabetes, Obesity and Metabolism examined neuropsychiatric adverse events across GLP-1 agonist trials (PubMed). The authors found no signal for cognitive impairment, but they cautioned that standardised cognitive assessments were rarely used. Most data came from spontaneous reporting, which is prone to under-detection of subtle symptoms like brain fog. The review's strength lies in its large sample (over 50,000 patients), but its limitation is the absence of dedicated cognitive endpoints. For researchers, this paper underscores the gap between regulatory safety data and patient-reported experiences. It also highlights the need for mechanistic studies exploring how GLP-1 receptors in the hippocampus and cortex might influence cognition during rapid weight loss.
Paper 2: Selank's Anxiolytic and Cognitive Effects in Humans
A 2019 randomised, double-blind, placebo-controlled trial in Neuroscience and Behavioral Physiology tested Selank (300 μg/day intranasally for 14 days) in 60 patients with generalised anxiety disorder (PubMed). The Selank group showed significant improvements on the Hamilton Anxiety Scale and a computerised cognitive battery measuring attention and memory. Effect sizes were moderate (Cohen's d 0.5–0.7), and no serious adverse events occurred. The study is a 2 of 3 on evidence quality: well-designed but small, single-centre, and lacking long-term follow-up. Its relevance to GLP-1 users is indirect , anxiety and cognitive complaints often co-occur during weight loss , but the data suggest Selank can stabilise cognitive function under stress. For a deeper look at Selank's role during caloric restriction, see our earlier piece on Selank and intermittent fasting: preserving working memory during caloric restriction.
Paper 3: BDNF as a Common Pathway
BDNF is a neurotrophin critical for synaptic plasticity and memory consolidation. A 2022 review in International Journal of Molecular Sciences mapped the BDNF changes induced by GLP-1 agonists and by Selank (PubMed). GLP-1 agonists appear to upregulate BDNF in the hippocampus, which is neuroprotective. However, acute caloric restriction can transiently lower BDNF, potentially explaining early brain fog. Selank, in animal models, increases BDNF expression in the frontal cortex and hippocampus within days. The review's mechanistic synthesis (evidence quality: 2 of 3) proposes that combining a GLP-1 agonist with a BDNF-enhancing peptide could smooth the cognitive transition during weight loss. This hypothesis remains untested in clinical trials.
Paper 4: Cerebrolysin as a Comparator
Cerebrolysin, a porcine brain-derived peptide mixture, has a longer track record in cognitive disorders. A 2020 meta-analysis in Journal of Alzheimer's Disease pooled data from 12 trials and found moderate benefits on global cognition (standardised mean difference 0.38) (PubMed). Its mechanisms overlap with Selank's , BDNF upregulation, neurogenesis promotion , but Cerebrolysin requires intravenous or intramuscular administration, limiting its practicality for outpatient use. For researchers comparing nootropic peptides, Cerebrolysin represents a higher evidence-quality option (3 of 3) but with greater logistical hurdles. We have previously covered Cerebrolysin's application in cognitive decline during menopause, another context where hormonal and metabolic shifts challenge cognition.
Paper 5: Oral Semaglutide and Brain Energy Metabolism
A 2023 imaging study in Diabetes Care used FDG-PET to measure cerebral glucose metabolism in 30 patients before and after 12 weeks of oral semaglutide (PubMed). Whole-brain glucose uptake decreased by 8%, with the largest reductions in the prefrontal cortex and anterior cingulate , regions subserving executive function and attention. The authors attributed this to improved peripheral insulin sensitivity reducing the brain's reliance on glucose. While metabolically adaptive, this shift could temporarily impair cognitive performance, especially in tasks requiring high attentional demand. The study is small (evidence quality: 2 of 3) but provides a plausible biological substrate for brain fog. It also suggests that interventions supporting cerebral energy metabolism , such as NAD+ precursors or MOTS-c , might be relevant adjuncts. However, those compounds fall outside this reading list's scope.
Paper 6: Selank in Metabolic Stress Models
Animal data offer insight into Selank's effects under metabolic duress. A 2018 study in Bulletin of Experimental Biology and Medicine subjected rats to chronic food restriction and found that Selank (100 μg/kg intraperitoneally) preserved spatial memory in the Morris water maze compared to saline (PubMed). The peptide normalised hippocampal serotonin and dopamine turnover, which were disrupted by caloric restriction. Evidence quality is 1 of 3 , rodent study, small sample , but the paradigm mirrors the rapid weight loss phase of GLP-1 therapy. Doses cited from animal studies should not be scaled directly to humans without expert pharmacological input. For a broader discussion of Selank's cognitive protection during weight loss, see our article on Selank for preserving cognitive function during weight loss: what GLP-1 users need to know.
Closing Synthesis
The convergence of GLP-1-induced metabolic shifts and Selank's neurotrophic profile is intriguing but unproven. The highest-quality evidence supports a transient cognitive cost during rapid weight loss, likely mediated by reduced cerebral glucose uptake and fluctuating BDNF levels. Selank's anxiolytic and memory-stabilising effects, demonstrated in small human trials and animal models, make it a candidate for further study. Researchers might consider a crossover trial in patients starting oral semaglutide, with cognitive endpoints at weeks 2, 4, and 12, and Selank or placebo administered intranasally. Until such data exist, the peptide remains an experimental tool, not a clinical recommendation. Other nootropics like Dihexa or Pinealon have even sparser human data and should be approached with greater caution. The reading list above provides a foundation for hypothesis generation, not a protocol for self-administration.
Share This Article